BURLINGTON, Mass. ,
July 14, 2011 /PRNewswire/ -- Palomar
Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and
developer of light-based systems for cosmetic treatments, will hold
its quarterly conference call of its 2011 second quarter financial
results on Thursday, July 28, 2011 at
11:30 AM Eastern Time. If you would
like to participate, please call (866) 800-8648 at 11:20 AM Eastern Time on that day.
A live webcast of Palomar's conference call will be available in
the Investor Relations' section of the Company's web site
www.palomarmedical.com. The online archive will be available one
hour after the call and continue through Thursday, August 4, 2011.
For more information on Palomar and its products, visit
Palomar's website at www.palomarmedical.com. To continue receiving
the most up-to-date information and latest news on Palomar as it
happens, sign up to receive automatic e-mail alerts by going to the
Investor Relations' section of the website.
About Palomar Medical Technologies, Inc.: Palomar is a
leading researcher and developer of laser- and light-based systems
for aesthetic treatments.
Palomar pioneered the optical hair removal field, when, in 1997,
it introduced the first high-powered laser hair removal system.
Since then, many of the major advances in light-based hair removal
have been based on Palomar technology.
As a pioneer of fractional technology, Palomar is an owner of
fundamental intellectual property in this area. In December 2009, Palomar received the first United
States Food and Drug Administration (FDA) clearance for the
treatment of stretch marks using a fractional non-ablative laser.
In September 2010, Palomar received
the first FDA clearance for a fractional ablative and fractional
non-ablative combination treatment.
In December 2006, Palomar became
the first company to receive a 510(k) over-the-counter (OTC)
clearance from the FDA for a new, patented, home-use, light-based
hair removal device. In June 2009,
Palomar became the first company to receive a 510(k) OTC clearance
from the FDA for a new, patented, home-use, laser device for the
treatment of periorbital wrinkles. OTC clearance allows these
products to be marketed and sold directly to consumers without a
prescription. Palomar introduced the PaloVia™ Skin Renewing Laser™
in December 2010.
There are now millions of laser- and light-based aesthetic
procedures performed around the world every year in physician
offices, clinics, spas, salons, and homes. Palomar is testing
many new and exciting applications to further advance the aesthetic
market and other surgical applications.
With the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements, including, but not limited to, statements relating to
new markets, future royalty amounts due from third parties,
development and introduction of new products, and financial and
operating projections. These forward-looking statements are neither
promises nor guarantees, but involve risk and uncertainties that
may individually or mutually impact the matters herein, and cause
actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but
are not limited to, results of future operations, technological
difficulties in developing or introducing new products, the results
of future research, lack of product demand and market acceptance
for current and future products, the effect of economic conditions,
challenges in managing joint ventures and research with third
parties and government contracts, the impact of competitive
products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained
for future products and additional applications, the results of
litigation, difficulties in collecting royalties, potential
infringement of third-party intellectual property rights, factors
affecting the Company's future income and resulting ability to
utilize its NOLs, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on
Form 10-K for the year ended December 31,
2010 and the Company's quarterly reports on Form 10-Q.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to release publicly the result
of any revisions to these forward-looking statements that may be
made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Contacts:
|
Kerry McAnistan
|
|
|
Investor Relations
Assistant
|
|
|
Palomar Medical Technologies,
Inc.
|
|
|
781-993-2411
|
|
|
ir@palomarmedical.com
|
|
|
|
SOURCE Palomar Medical Technologies, Inc.